Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment With CTL019/CTL119 in Late Relapse of B-Cell Lymphomas
NCT04419909Phase 1Withdrawn
- Sponsor
- University of Pennsylvania
- Start
- May 2026
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tisagenlecleucel and huCART-19 in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by University of Pennsylvania. Primary endpoint: Treatment-related adverse events at 1 year. Planned start May 2026; status: withdrawn.
02
Drugs
tisagenlecleucelhuCART-19
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04419909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419909.